Wedbush Starts GTX Inc. (GTXI) at Outperform; Advanced Clinical Programs Are Underappreciated

July 20, 2011 6:47 AM EDT
Get Alerts GTXI Hot Sheet
Price: $1.20 --0%

Rating Summary:
    1 Buy, 4 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Wedbush initiates coverage on GTX Inc. (NASDAQ: GTXI) with an Outperform. PT $13.

Wedbush analyst says, "Ostarine, the company’s lead selective androgen receptor modulator (SARM) is entering Phase III trials to treat and prevent muscle wasting in non-small cell lung cancer (NSCLC) patients. Ostarine has demonstrated statistically significant increases in lean body mass (LBM) in cancer patients and also demonstrated clinical benefit in stair climb power...Top-line data from the Capesaris Phase IIb trial could read out in Q4:11; initial data from Ostarine’s Phase III program could read out in Q1:13."

For more ratings news on GTX Inc. click here and for the rating history of GTX Inc. click here.

Shares of GTX Inc. closed at $4.31 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

New Coverage